Phase 2a ulcerative colitis ("UC") data indicates real promise for the ABX-464 in the $15bn inflammatory bowel disease ("IBD") market. A small early stage trial, positive read-out on all key parameters suggests real benefits from this oral once a day drug for patients seeking to avoid repeated intravenous infusions or at worst surgical bowel removal. Already showing promise in the depletion of latent HIV reservoirs, these new data should significantly de-risk the drug's path to market potentiall ....
06 Sep 2018
Remarkable data opens door to $15bn IBD market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Remarkable data opens door to $15bn IBD market
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
06 Sep 2018 -
Author:
Chris Redhead -
Pages:
5
Phase 2a ulcerative colitis ("UC") data indicates real promise for the ABX-464 in the $15bn inflammatory bowel disease ("IBD") market. A small early stage trial, positive read-out on all key parameters suggests real benefits from this oral once a day drug for patients seeking to avoid repeated intravenous infusions or at worst surgical bowel removal. Already showing promise in the depletion of latent HIV reservoirs, these new data should significantly de-risk the drug's path to market potentiall ....